Genomics and proteomics in liver fibrosis and cirrhosis

Fibrogenesis & Tissue Repair

Scott L Friedman¹  Virginia Hernandez-Gea¹  Rebekka A Hannivoort² 

[1] Department of Medicine/Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA;Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

关键词: proteomics;    microarray;    mass spectrometry;    liver fibrosis;    genomics;    cirrhosis;   

Others  :  804003
DOI  :  10.1186/1755-1536-5-1

 received in 2011-10-28, accepted in 2012-01-03,  发布年份 2012

【 摘 要 】

Genomics and proteomics have become increasingly important in biomedical science in the past decade, as they provide an opportunity for hypothesis-free experiments that can yield major insights not previously foreseen when scientific and clinical questions are based only on hypothesis-driven approaches. Use of these tools, therefore, opens new avenues for uncovering physiological and pathological pathways. Liver fibrosis is a complex disease provoked by a range of chronic injuries to the liver, among which are viral hepatitis, (non-) alcoholic steatohepatitis and autoimmune disorders. Some chronic liver patients will never develop fibrosis or cirrhosis, whereas others rapidly progress towards cirrhosis in a few years. This variety can be caused by disease-related factors (for example, viral genotype) or host-factors (genetic/epigenetic). It is vital to establish accurate tools to identify those patients at highest risk for disease severity or progression in order to determine who are in need of immediate therapies. Moreover, there is an urgent imperative to identify non-invasive markers that can accurately distinguish mild and intermediate stages of fibrosis. Ideally, biomarkers can be used to predict disease progression and treatment response, but these studies will take many years due to the requirement for lengthy follow-up periods to assess outcomes. Current genomic and proteomic research provides many candidate biomarkers, but independent validation of these biomarkers is lacking, and reproducibility is still a key concern. Thus, great opportunities and challenges lie ahead in the field of genomics and proteomics, which, if successful, could transform the diagnosis and treatment of chronic fibrosing liver diseases.

【 授权许可】

   
2012 Hannivoort et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Bataller R, Brenner DA: Liver fibrosis. J Clin Invest 2005, 115:209-18.
• [2]Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-72.
• [3]Juran BD, Lazaridis KN: Applying genomics to the study of complex disease. Semin Liver Dis 2007, 27:3-12.
• [4]Osterreicher CH, Stickel F, Brenner DA: Genomics of liver fibrosis and cirrhosis. Semin Liver Dis 2007, 27:28-43.
• [5]Juran BD, Lazaridis KN: Genomics and complex liver disease: Challenges and opportunities. Hepatology 2006, 44:1380-90.
• [6]Grant A, Neuberger J: Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999, 45(Suppl 4):IV1-IV11.
• [7]McGill DB, Rakela J, Zinsmeister AR, Ott BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990, 99:1396-400.
• [8]Piccinino F, Sagnelli E, Pasquale G, Giusti G: Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-73.
• [9]Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-8.
• [10]Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F: Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003, 38:427-32.
• [11]Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-906.
• [12]Cox LA, Schlabritz-Loutsevitch N, Hubbard GB, Nijland MJ, McDonald TJ, Nathanielsz PW: Gene expression profile differences in left and right liver lobes from mid-gestation fetal baboons: a cautionary tale. J Physiol 2006, 572:59-66.
• [13]Skripenova S, Trainer TD, Krawitt EL, Blaszyk H: Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007, 60:321-4.
• [14]Bedossa P, Dargere D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-57.
• [15]Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L: Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 2003, 73:386-402.
• [16]Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-26.
• [17]Martinez SM, Crespo G, Navasa M, Forns X: Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-35.
• [18]Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-75.
• [19]Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
• [20]Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Thabut D, Myers RP, Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 1:3.
• [21]Smith JO, Sterling RK: Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009, 30:557-76.
• [22]Rockey DC, Bissell DM: Noninvasive measures of liver fibrosis. Hepatology 2006, 43:S113-20.
• [23]Shaheen AA, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102:2589-600.
• [24]Trinchet JC, Hartmann DJ, Pateron D, Laarif M, Callard P, Ville G, Beaugrand M: Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol 1991, 12:139-44.
• [25]Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993, 342:895-8.
• [26]Gallorini A, Plebani M, Pontisso P, Chemello L, Masiero M, Mantovani G, Alberti A: Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon. Liver 1994, 14:257-64.
• [27]Yabu K, Kiyosawa K, Mori H, Matsumoto A, Yoshizawa K, Tanaka E, Furuta S: Serum collagen type IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C. Scand J Gastroenterol 1994, 29:474-9.
• [28]Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ: Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci 1999, 44:624-30.
• [29]Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002, 316:71-81.
• [30]Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H: The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009, 16:418-29.
• [31]Morra R, Munteanu M, Bedossa P, Dargere D, Janneau JL, Paradis V, Ratziu V, Charlotte F, Thibault V, Imbert-Bismut F, Poynard T: Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007, 26:847-58.
• [32]Gressner OA, Weiskirchen R, Gressner AM: Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-13.
• [33]Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A: New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006, 12:7604-12.
• [34]Mas VR, Fisher RA, Archer KJ, Maluf DG: Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics 2009, 6:421-31.
• [35]Kuramitsu Y, Nakamura K: Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics 2005, 2:589-601.
• [36]Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-13.
• [37]Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J, Goodlett D, Berger JP, Gunter B, Linseley PS, Stoughton RB, Aebersold R, Collins SJ, Hanlon WA, Hood LE: Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 2004, 3:960-9.
• [38]Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO: Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999, 23:41-6.
• [39]Sellick GS, Longman C, Tolmie J, Newbury-Ecob R, Geenhalgh L, Hughes S, Whiteford M, Garrett C, Houlston RS: Genomewide linkage searches for Mendelian disease loci can be efficiently conducted using high-density SNP genotyping arrays. Nucleic Acids Res 2004, 32:e164.
• [40]Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipshutz R, Chee M, Lander ES: Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998, 280:1077-82.
• [41]Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD: Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003, 302:2141-4.
• [42]Yamamoto M, Wakatsuki T, Hada A, Ryo A: Use of serial analysis of gene expression (SAGE) technology. J Immunol Methods 2001, 250:45-66.
• [43]Ruijter JM, Van Kampen AH, Baas F: Statistical evaluation of SAGE libraries: consequences for experimental design. Physiol Genomics 2002, 11:37-44.
• [44]Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
• [45]Capelo JL, Carreira R, Diniz M, Fernandes L, Galesio M, Lodeiro C, Santos HM, Vale G: Overview on modern approaches to speed up protein identification workflows relying on enzymatic cleavage and mass spectrometry-based techniques. Anal Chim Acta 2009, 650:151-9.
• [46]Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, Pognan F, Hawkins E, Currie I, Davison M: Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001, 1:377-96.
• [47]Unlu M, Morgan ME, Minden JS: Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 1997, 18:2071-7.
• [48]Schwartz JC, Senko MW, Syka JE: A two-dimensional quadrupole ion trap mass spectrometer. J Am Soc Mass Spectrom 2002, 13:659-69.
• [49]Marshall AG, Hendrickson CL, Jackson GS: Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom Rev 1998, 17:1-35.
• [50]Hardman M, Makarov AA: Interfacing the orbitrap mass analyzer to an electrospray ion source. Anal Chem 2003, 75:1699-705.
• [51]Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Graham Cooks R: The Orbitrap: a new mass spectrometer. J Mass Spectrom 2005, 40:430-43.
• [52]Hutchens TA: Automaticity and reading in learning-disabled college students. Ann N Y Acad Sci 1993, 682:357-8.
• [53]Issaq HJ, Veenstra TD, Conrads TP, Felschow D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002, 292:587-92.
• [54]De Bock M, de Seny D, Meuwis MA, Chapelle JP, Louis E, Malaise M, Merville MP, Fillet M: Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J Biomed Biotechnol 2010, 2010:906082.
• [55]Domon B, Aebersold R: Mass spectrometry and protein analysis. Science 2006, 312:212-7.
• [56]MacBeath G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science 2000, 289:1760-3.
• [57]Low TY, Leow CK, Salto-Tellez M, Chung MC: A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 2004, 4:3960-74.
• [58]Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stuhler K, Graf J, Roeb E: Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006, 6:6538-48.
• [59]Shepard BD, Tuma DJ, Tuma PL: Chronic ethanol consumption induces global hepatic protein hyperacetylation. Alcohol Clin Exp Res 2010, 34:280-91.
• [60]Andringa KK, King AL, Eccleston HB, Mantena SK, Landar A, Jhala NC, Dickinson DA, Squadrito GL, Bailey SM: Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. Am J Physiol Gastrointest Liver Physiol 2010, 298:G732-45.
• [61]Kharbanda KK, Vigneswara V, McVicker BL, Newlaczyl AU, Bailey K, Tuma D, Ray DE, Carter WG: Proteomics reveal a concerted upregulation of methionine metabolic pathway enzymes, and downregulation of carbonic anhydrase-III, in betaine supplemented ethanol-fed rats. Biochem Biophys Res Commun 2009, 381:523-7.
• [62]Liu EH, Chen MF, Yeh TS, Ho YP, Wu RC, Chen TC, Jan YY, Pan TL: A useful model to audit liver resolution from cirrhosis in rats using functional proteomics. J Surg Res 2007, 138:214-23.
• [63]Kirpich IA, Gobejishvili LN, Bon Homme M, Waigel S, Cave M, Arteel G, Barve SS, McClain CJ, Deaciuc IV: Integrated hepatic transcriptome and proteome analysis of mice with high-fat diet-induced nonalcoholic fatty liver disease. J Nutr Biochem 2011, 22:38-45.
• [64]Zhang X, Yang J, Guo Y, Ye H, Yu C, Xu C, Xu L, Wu S, Sun W, Wei H, Gao X, Zhu Y, Qian X, Jiang Y, Li Y, He F: Functional proteomic analysis of nonalcoholic fatty liver disease in rat models: enoyl-coenzyme a hydratase down-regulation exacerbates hepatic steatosis. Hepatology 2010, 51:1190-9.
• [65]Kristensen DB, Kawada N, Imamura K, Miyamoto Y, Tateno C, Seki S, Kuroki T, Yoshizato K: Proteome analysis of rat hepatic stellate cells. Hepatology 2000, 32:268-77.
• [66]Kawada N, Kristensen DB, Asahina K, Nakatani K, Minamiyama Y, Seki S, Yoshizato K: Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem 2001, 276:25318-23.
• [67]Deng X, Liang J, Lin ZX, Wu FS, Zhang YP, Zhang ZW: Natural taurine promotes apoptosis of human hepatic stellate cells in proteomics analysis. World J Gastroenterol 2010, 16:1916-23.
• [68]Yokoyama Y, Terai S, Ishikawa T, Aoyama K, Urata Y, Marumoto Y, Nishina H, Nakamura K, Okita K, Sakaida I: Proteomic analysis of serum marker proteins in recipient mice with liver cirrhosis after bone marrow cell transplantation. Proteomics 2006, 6:2564-70.
• [69]Shimada T, Nakanishi T, Toyama A, Yamauchi S, Kanzaki A, Fujiwake H, Sato TA, Ikegawa M: Potential implications for monitoring serum bile acid profiles in circulation with serum proteome for carbon tetrachloride-induced liver injury/regeneration model in mice. J Proteome Res 2010, 9:4490-500.
• [70]Smyth R, Lane CS, Ashiq R, Turton JA, Clarke CJ, Dare TO, York MJ, Griffiths W, Munday MR: Proteomic investigation of urinary markers of carbon-tetrachloride-induced hepatic fibrosis in the Hanover Wistar rat. Cell Biol Toxicol 2009, 25:499-512.
• [71]Walters KA, Katze MG: Using high-throughput genomics to study hepatitis C: what determines the outcome of infection? Antiviral Res 2009, 81:198-208.
• [72]Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RL Jr, Larson AM, Yeh MM, Camp DG, Smith RD, Katze MG: Proteomic profiling of human liver biopsies: hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007, 46:649-57.
• [73]Molleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornoe I, Schlosser A, Kloppel G, Schmiegel W, Meyer HE, Holmskov U, Stuhler K: Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009, 49:1257-66.
• [74]White IR, Patel K, Symonds WT, Dev A, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P, Gattu M, Rockey DC, Berrey MM, McHutchison JG: Serum proteomic analysis focused on fibrosis in patients with hepatitis C virus infection. J Transl Med 2007, 5:33.
• [75]Chen L, Borozan I, Sun J, Guindi M, Fischer S, Feld J, Anand N, Heathcote J, Edwards AM, McGilvray ID: Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010, 138:1123-33. e1-3
• [76]Gangadharan B, Antrobus R, Dwek RA, Zitzmann N: Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007, 53:1792-9.
• [77]Suzman DL, McLaughlin M, Hu Z, Kleiner DE, Wood B, Lempicki RA, Mican JM, Suffredini A, Masur H, Polis MA, Kottilil S: Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008, 22:1433-9.
• [78]Yang L, Rudser KD, Higgins L, Rosen HR, Zaman A, Corless CL, David L, Gourley GR: Novel biomarker candidates to predict hepatic fibrosis in hepatitis c identified by serum proteomics. Dig Dis Sci 2011, 56:3305-15.
• [79]Corradi F, Piscaglia F, Flori S, D'Errico-Grigioni A, Vasuri F, Tame MR, Andreone P, Boni P, Gianstefani A, Bolondi L: Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig Liver Dis 2009, 41:217-25.
• [80]Cheung KJ, Libbrecht L, Tilleman K, Deforce D, Colle I, Van Vlierberghe H: Galectin-3-binding protein: a serological and histological assessment in accordance with hepatitis C-related liver fibrosis. Eur J Gastroenterol Hepatol 2010, 22:1066-73.
• [81]Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ, Layden TJ, Wright TL, White T, Cheung RC: A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306.
• [82]Marcolongo M, Young B, Dal Pero F, Fattovich G, Peraro L, Guido M, Sebastiani G, Palu G, Alberti A: A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009, 50:1038-44.
• [83]Pradat P, Trepo E, Potthoff A, Bakshi R, Young B, Trepo C, Lagier R, Moreno C, Lemmers A, Gustot T, Degre D, Adler M, Wedemeyer H: The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2010, 51:356-7.
• [84]Narayan R, Gangadharan B, Hantz O, Antrobus R, Garcia A, Dwek RA, Zitzmann N: Proteomic analysis of HepaRG cells: a novel cell line that supports hepatitis B virus infection. J Proteome Res 2009, 8:118-22.
• [85]Dienstag JL, McHutchison JG: American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006, 130:225-30.
• [86]Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, Boyer N, Martinot-Peignoux M, Valla D, Vidaud M, Marcellin P: Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008, 57:516-24.
• [87]Hayashida K, Daiba A, Sakai A, Tanaka T, Kaji K, Inaba N, Ando S, Kajiyama N, Terasaki H, Abe A, Ogasawara M, Kohara M, Harada M, Okanoue T, Ito S, Kaneko S: Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol 2005, 3:1253-9.
• [88]Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW: Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007, 46:1548-63.
• [89]Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J: IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-4.
• [90]Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-9.
• [91]Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG: Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010, 139:1181-9.
• [92]Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH: Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008, 105:7034-9.
• [93]Devitt EJ, Power KA, Lawless MW, Browne JA, Gaora PO, Gallagher WM, Crowe J: Early proteomic analysis may allow noninvasive identification of hepatitis C response to treatment with pegylated interferon alpha-2b and ribavirin. Eur J Gastroenterol Hepatol 2011, 23:177-83.
• [94]Sun W, Zhong F, Zhi L, Zhou G, He F: Systematic -omics analysis of HBV-associated liver diseases. Cancer Lett 2009, 286:89-95.
• [95]Zhang L, Peng X, Zhang Z, Feng Y, Jia X, Shi Y, Yang H, Zhang X, Liu L, Yin L, Yuan Z: Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem 2010, 110:219-28.
• [96]Lu Y, Liu J, Lin C, Wang H, Jiang Y, Wang J, Yang P, He F: Peroxiredoxin 2: a potential biomarker for early diagnosis of hepatitis B virus related liver fibrosis identified by proteomic analysis of the plasma. BMC Gastroenterol 2010, 10:115.
• [97]Marrocco C, Rinalducci S, Mohamadkhani A, D'Amici GM, Zolla L: Plasma gelsolin protein: a candidate biomarker for hepatitis B-associated liver cirrhosis identified by proteomic approach. Blood Transfus 2010, 8(Suppl 3):s105-12.
• [98]Mohamadkhani A, Jazii FR, Sayehmiri K, Jafari-Nejad S, Montaser-Kouhsari L, Poustchi H, Montazeri G: Plasma myeloperoxidase activity and apolipoprotein A-1 expression in chronic hepatitis B patients. Arch Iran Med 2011, 14:254-8.
• [99]Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ: Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005, 51:328-35.
• [100]Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003, 39:222-30.
• [101]Wang J, Jiang D, Zhang H, Lv S, Rao H, Fei R, Wei L: Proteome responses to stable hepatitis B virus transfection and following interferon alpha treatment in human liver cell line HepG2. Proteomics 2009, 9:1672-82.
• [102]Seth D, Gorrell MD, Cordoba S, McCaughan GW, Haber PS: Intrahepatic gene expression in human alcoholic hepatitis. J Hepatol 2006, 45:306-20.
• [103]Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V: A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-74.
• [104]Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N: Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-20.
• [105]Ulukaya E, Yilmaz Y, Moshkovskii S, Karpova M, Pyatnitskiy M, Atug O, Dolar E: Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Scand J Gastroenterol 2009, 44:1471-6.
• [106]Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, Younossi ZM: A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46:166-72.
• [107]Wilfred de Alwis NM, Day CP: Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008, 8:156-63.
• [108]Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL: A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009, 9:271.
• [109]Charlton M: Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol 2007, 102:409-11.
• [110]Juran BD, Lazaridis KN: Genetics and genomics of primary biliary cirrhosis. Clin Liver Dis 2008, 12:349-65. ix
• [111]Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW: Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001, 49:565-76.
• [112]Li YZ, Hu CJ, Leng XM, Zhao GF, Li N, Xu Y: Promising diagnostic biomarkers for primary biliary cirrhosis identified with magnetic beads and MALDI-TOF-MS. Anat Rec (Hoboken) 2009, 292:455-60.
• [113]Tahiri F, Le Naour F, Huguet S, Lai-Kuen R, Samuel D, Johanet C, Saubamea B, Tricottet V, Duclos-Vallee JC, Ballot E: Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology 2008, 47:937-48.
• [114]Song H, Sokolov M: Analysis of protein expression and compartmentalization in retinal neurons using serial tangential sectioning of the retina. J Proteome Res 2009, 8:346-51.
• [115]Bowlus CL, Seeley EH, Roder J, Grigorieva J, Roder H, Caprioli RM, Gershwin M: In situ mass spectrometry of autoimmune liver diseases. Cell Mol Immunol 2011, 8:237-42.
• [116]Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27:55-76.
• [117]Makridakis M, Vlahou A: Secretome proteomics for discovery of cancer biomarkers. J Proteomics 2010, 73:2291-305.
• [118]Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, Liu F, You XF, Han YX, Zhao ZY, Cen S, Li JR, Song DQ, Jiang JD: Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology 2010, 52:845-53.